NCT06404606

Brief Summary

Osteoarthritis is a chronic inflammatory disease that directly affects the quality of life and financial burden. The understanding of the mechanism and available intervention strategies can not minimize its incidence that increased by 1/10 since 1990. The combination of black cumin and turmeric with sound waves is not well known.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jun 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 5, 2024

Completed
3 days until next milestone

First Posted

Study publicly available on registry

May 8, 2024

Completed
1 month until next milestone

Study Start

First participant enrolled

June 15, 2024

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2024

Completed
15 days until next milestone

Study Completion

Last participant's last visit for all outcomes

January 15, 2025

Completed
Last Updated

June 3, 2024

Status Verified

May 1, 2024

Enrollment Period

7 months

First QC Date

May 5, 2024

Last Update Submit

May 31, 2024

Conditions

Keywords

OsteoarthritisQuantum Acoustic WavesBlack Cumin &Turmeric.

Outcome Measures

Primary Outcomes (1)

  • Inflammatory Markers

    The blood sample will be taken for assessment of Inflammatory cytokines interleukin (IL)-6, IL,10, IL-17, Tissue necrotic factor (TNF), Complete Blood Count (CBC), CRP, ESR, RA factor, Anti-CCP and Vitamin D for functional parameters.

    Baseline (0-week) and 12th week

Secondary Outcomes (2)

  • Pain

    Baseline (0-week), 4-week, 8-week & 12-week.

  • Knee Injury and Osteoarthritis Outcome Score

    Baseline (0-week), 4-week, 8-week & 12-week.

Study Arms (3)

Group A (Black Cumin & Turmeric)

ACTIVE COMPARATOR

Participants will receive one capsule of black cumin and turmeric thrice per week (Alternate days) for 12 weeks.

Combination Product: Black cumin and turmeric with Quantum Acoustic Waves (QAW)

Group B (Black Cumin & Turmeric along with Quantum Acoustic Waves)

ACTIVE COMPARATOR

Participants will receive one capsule of black cumin and turmeric along with Quantum Acoustic Waves (QAW) three days per week for 12 weeks

Combination Product: Black cumin and turmeric with Quantum Acoustic Waves (QAW)

Group C (Quantum Acoustic Waves)

ACTIVE COMPARATOR

Participants will receive Quantum Acoustic Waves (QAW) three days per week for 12 weeks

Combination Product: Black cumin and turmeric with Quantum Acoustic Waves (QAW)

Interventions

Black cumin and turmeric are known to be helpful in reduction of inflammation of human body so it will be used in combination with Quantum Acoustic Waves (QAW) to determine effects on initial degenerative changes in osteoarthritis.

Group A (Black Cumin & Turmeric)Group B (Black Cumin & Turmeric along with Quantum Acoustic Waves)Group C (Quantum Acoustic Waves)

Eligibility Criteria

Age45 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Both genders age between 45 to 60 years.
  • Rheumatoid Arthritis (RA) negative.
  • C-reactive protein (CRP)negative.
  • Erythrocyte Sedimentation Rate (ESR) below 30.
  • No intake of Anti-inflammatory drugs (NSAIDS, steroids) during the last 02 weeks.
  • Grade 2 and Grade 3 Osteoarthritis as per kellegran criteria.
  • Body Mass Index (BMI) between 18.5 kg/m2 to 29.9 kg/m2.
  • Vitamin D above 30 ng/dl.

You may not qualify if:

  • Infective arthritis.
  • Reactive arthritis.
  • Major Gastrointestinal or cardiovascular disease/disorder.
  • Musculoskeletal injury or disorder that limits participation.
  • Patients who are not willing to participate.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Innovative Health Concepts & Research Center

Lahore, Punjab Province, 54700, Pakistan

Location

Related Publications (14)

  • March L, Cross M, Lo C, Arden NK, Gates L, Leyland K, et al. Osteoarthritis: A Serious Disease: Submitted to the US Food and Drug Administration. 2016.

    RESULT
  • Safiri S, Kolahi AA, Smith E, Hill C, Bettampadi D, Mansournia MA, Hoy D, Ashrafi-Asgarabad A, Sepidarkish M, Almasi-Hashiani A, Collins G, Kaufman J, Qorbani M, Moradi-Lakeh M, Woolf AD, Guillemin F, March L, Cross M. Global, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the Global Burden of Disease Study 2017. Ann Rheum Dis. 2020 Jun;79(6):819-828. doi: 10.1136/annrheumdis-2019-216515. Epub 2020 May 12.

  • Cui A, Li H, Wang D, Zhong J, Chen Y, Lu H. Global, regional prevalence, incidence and risk factors of knee osteoarthritis in population-based studies. EClinicalMedicine. 2020 Nov 26;29-30:100587. doi: 10.1016/j.eclinm.2020.100587. eCollection 2020 Dec.

  • Abramoff B, Caldera FE. Osteoarthritis: Pathology, Diagnosis, and Treatment Options. Med Clin North Am. 2020 Mar;104(2):293-311. doi: 10.1016/j.mcna.2019.10.007. Epub 2019 Dec 18.

  • Hu Y, Chen X, Wang S, Jing Y, Su J. Subchondral bone microenvironment in osteoarthritis and pain. Bone Res. 2021 Mar 17;9(1):20. doi: 10.1038/s41413-021-00147-z.

  • van den Bosch MHJ. Osteoarthritis year in review 2020: biology. Osteoarthritis Cartilage. 2021 Feb;29(2):143-150. doi: 10.1016/j.joca.2020.10.006. Epub 2020 Nov 24.

  • Geyer M, Schonfeld C. Novel Insights into the Pathogenesis of Osteoarthritis. Curr Rheumatol Rev. 2018;14(2):98-107. doi: 10.2174/1573397113666170807122312.

  • Kulkarni P, Martson A, Vidya R, Chitnavis S, Harsulkar A. Pathophysiological landscape of osteoarthritis. Adv Clin Chem. 2021;100:37-90. doi: 10.1016/bs.acc.2020.04.002. Epub 2020 May 29.

  • Geraghty T, Winter DR, Miller RJ, Miller RE, Malfait AM. Neuroimmune interactions and osteoarthritis pain: focus on macrophages. Pain Rep. 2021 Mar 9;6(1):e892. doi: 10.1097/PR9.0000000000000892. eCollection 2021.

  • Jang S, Lee K, Ju JH. Recent Updates of Diagnosis, Pathophysiology, and Treatment on Osteoarthritis of the Knee. Int J Mol Sci. 2021 Mar 5;22(5):2619. doi: 10.3390/ijms22052619.

  • Coaccioli S, Sarzi-Puttini P, Zis P, Rinonapoli G, Varrassi G. Osteoarthritis: New Insight on Its Pathophysiology. J Clin Med. 2022 Oct 12;11(20):6013. doi: 10.3390/jcm11206013.

  • Amin B, Hosseinzadeh H. Black Cumin (Nigella sativa) and Its Active Constituent, Thymoquinone: An Overview on the Analgesic and Anti-inflammatory Effects. Planta Med. 2016 Jan;82(1-2):8-16. doi: 10.1055/s-0035-1557838. Epub 2015 Sep 14.

  • Altman J. Information processing concerning moving sound sources in the auditory centers and its utilization by brain integrative and motor structures. Auditory pathway: structure and function. 1988:349-54.

    RESULT
  • Xu M, Wang L, Wu S, Dong Y, Chen X, Wang S, Li X, Zou C. Review on experimental study and clinical application of low-intensity pulsed ultrasound in inflammation. Quant Imaging Med Surg. 2021 Jan;11(1):443-462. doi: 10.21037/qims-20-680.

MeSH Terms

Conditions

Osteoarthritis

Interventions

Curcumin

Condition Hierarchy (Ancestors)

ArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic Diseases

Intervention Hierarchy (Ancestors)

DiarylheptanoidsHeptanesAlkanesHydrocarbons, AcyclicHydrocarbonsOrganic ChemicalsCatecholsPhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, Cyclic

Study Officials

  • Muhammad Faheem Afzal, *PhD

    PSRD Hospital/IHC&RC

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Muhammad Faheem Afzal, *PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, CARE PROVIDER
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 5, 2024

First Posted

May 8, 2024

Study Start

June 15, 2024

Primary Completion

December 31, 2024

Study Completion

January 15, 2025

Last Updated

June 3, 2024

Record last verified: 2024-05

Data Sharing

IPD Sharing
Will not share

Locations